KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2023 - 2025)

Historic Long-Term Deferred Tax for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2025 value amounting to $98.6 million.

  • Alnylam Pharmaceuticals' Long-Term Deferred Tax changed N/A to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.6 million, marking a year-over-year change of. This contributed to the annual value of $116.9 million for FY2024, which is 105694.49% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Long-Term Deferred Tax of $98.6 million as of Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $116.9 million in Q4 2024 and a low of $10.1 million during Q4 2023
  • In the last 3 years, Alnylam Pharmaceuticals' Long-Term Deferred Tax had a median value of $104.4 million in 2025 and averaged $87.4 million.
  • Data for Alnylam Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY increase of 105694.49% (in 2024) and a maximum YoY decrease of 105694.49% (in 2024) over the last 5 years.
  • Over the past 3 years, Alnylam Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $10.1 million in 2023, then surged by 1056.94% to $116.9 million in 2024, then fell by 15.66% to $98.6 million in 2025.
  • Its Long-Term Deferred Tax stands at $98.6 million for Q3 2025, versus $104.4 million for Q2 2025 and $107.2 million for Q1 2025.